Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

670820

Sigma-Aldrich

Pam3-Cys-OH

≥98.0% (TLC), for peptide synthesis

Sinónimos:

N-α-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-L-cysteine

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C54H103NO7S
Número de CAS:
87420-41-5
Peso molecular:
910.46
MDL number:
MFCD00153468
UNSPSC Code:
12352209
eCl@ss:
32160406
PubChem Substance ID:
24885087
NACRES:
NA.22

Nombre del producto

Pam3-Cys-OH, ≥98.0% (TLC)

Quality Level

100

assay

≥98.0% (TLC)

reaction suitability

reaction type: solution phase peptide synthesis

application(s)

peptide synthesis

SMILES string

CCCCCCCCCCCCCCCC(=O)N[C@@H](CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(O)=O

InChI

1S/C54H103NO7S/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-51(56)55-50(54(59)60)48-63-47-49(62-53(58)45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)46-61-52(57)44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h49-50H,4-48H2,1-3H3,(H,55,56)(H,59,60)/t49?,50-/m0/s1

InChI key

PZFZLRNAOHUQPH-GOOVXGPGSA-N

Categorías relacionadas

General description

Pam3-Cys-OH is a lipopeptide containing a cysteine residue at the C-terminus, often used in solid phase peptide synthesis.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
BCCJ7225
BCCD0173
BCCC0039
BCBV8395
BCBQ5485V

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Lipoconjugates for the noncovalent generation of microarrays in biochemical and cellular assays
A Hoff, et al.
Chembiochem, 3, 1183-1191 (2002)
Nishi Shakya et al.
Peptides, 32(10), 2131-2133 (2011-10-01)
Prophylactic potential of synthetic bacterial lipopeptide and a TLR2 agonist, Pam3Cys was first evaluated against experimental visceral leishmaniasis in rodent model. After establishing the potential its effect on therapeutic efficacy of miltefosine was also studied. Pam3Cys showed 74.64% inhibition in
Peter M Moyle et al.
Current medicinal chemistry, 15(5), 506-516 (2008-02-22)
Despite the important role of adjuvants for vaccine development, relatively few adjuvants have been successfully incorporated into vaccines intended for human administration. This is in part due to the high toxicity associated with many experimental adjuvants. This lack of choice
Pitchaimani Kandasamy et al.
The Journal of biological chemistry, 286(10), 7841-7853 (2011-01-06)
Mycoplasma pneumoniae is a human pathogen causing respiratory infections that are also associated with serious exacerbations of chronic lung diseases. Membranes and lipoproteins from M. pneumoniae induced a 4-fold increase in arachidonic acid (AA) release from RAW264.7 and a 2-fold
Sudha Natarajan et al.
Shock (Augusta, Ga.), 33(2), 162-169 (2009-06-03)
LPS challenge causes potent activation of innate immunity. Because LPS is ubiquitously present in ambient air, repeated inhalation may lead to activation of the pulmonary immune response. If this activation is unregulated, chronic LPS inhalation would lead to persistent inflammation
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico